These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7732591)

  • 21. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations and altered expression of p16INK4 in human cancer.
    Okamoto A; Demetrick DJ; Spillare EA; Hagiwara K; Hussain SP; Bennett WP; Forrester K; Gerwin B; Serrano M; Beach DH
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11045-9. PubMed ID: 7972006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias.
    Ragione FD; Iolascon A
    Leuk Lymphoma; 1997 Mar; 25(1-2):23-35. PubMed ID: 9130611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16INK4 mutations and altered expression in human tumors and cell lines.
    Okamoto A; Demetrick DJ; Spillare EA; Hagiwara K; Hussain SP; Bennett WP; Forrester K; Gerwin B; Greenblatt MS; Serrano M
    Cold Spring Harb Symp Quant Biol; 1994; 59():49-57. PubMed ID: 7587103
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of the cyclin-dependent kinase inhibitors in the development of cancer.
    Hirama T; Koeffler HP
    Blood; 1995 Aug; 86(3):841-54. PubMed ID: 7620180
    [No Abstract]   [Full Text] [Related]  

  • 27. Cyclin-dependent kinase inhibitors in human neoplasms.
    Miller CW; Koeffler HP
    Leukemia; 1997 Apr; 11 Suppl 3():370-1. PubMed ID: 9209393
    [No Abstract]   [Full Text] [Related]  

  • 28. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
    Tsihlias J; Kapusta L; Slingerland J
    Annu Rev Med; 1999; 50():401-23. PubMed ID: 10073286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell cycle--molecular mechanisms and therapeutic perspectives in oncology.
    Ganchevska PG; Sarafian VS
    Folia Med (Plovdiv); 2004; 46(1):9-14. PubMed ID: 15362806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.
    Cordon-Cardo C
    Am J Pathol; 1995 Sep; 147(3):545-60. PubMed ID: 7677168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation and function of the cyclin-dependent kinase inhibitor p16CDKN2.
    Peters G; Parry D; Hara E; Hall M; Bates S; Palmero I
    Leukemia; 1997 Apr; 11 Suppl 3():352-5. PubMed ID: 9209387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
    Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
    Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell division cycle alterations and human tumors.
    Della Ragione F; Borriello A; Della Pietra V; Cucciolla V; Oliva A; Barbarisi A; Iolascon A; Zappia V
    Adv Exp Med Biol; 1999; 472():73-88. PubMed ID: 10736618
    [No Abstract]   [Full Text] [Related]  

  • 35. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
    Platz A; Hansson J; Ringborg U
    Int J Cancer; 1998 Sep; 78(1):13-5. PubMed ID: 9724087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development.
    Chellappan SP; Giordano A; Fisher PB
    Curr Top Microbiol Immunol; 1998; 227():57-103. PubMed ID: 9479826
    [No Abstract]   [Full Text] [Related]  

  • 37. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells.
    Cipriano SC; Chen YQ
    Oncogene; 1998 Sep; 17(12):1549-56. PubMed ID: 9794232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p27 and leukemia: cell cycle and beyond.
    Roy A; Banerjee S
    J Cell Physiol; 2015 Mar; 230(3):504-9. PubMed ID: 25205053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cyclin D, CDK4 and p16 expression in colorectal cancer].
    Ikeda K; Monden T; Tsujie M; Izawa H; Yamamoto H; Ohnishi T; Ohue M; Sekimoto M; Tomita N; Monden M
    Nihon Rinsho; 1996 Apr; 54(4):1054-9. PubMed ID: 8920673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.